Article
Neoadjuvant hormones: 8-months regimen appears to be no better than3-month regimen
Eight months of neoadjuvant hormone therapy prior to radiation therapyappears to offer no significant advantage over the standard of 3 monthsof therapy, at least in low- and intermediate-risk prostate cancer patients.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Related Content
